Showing results (101-110 of 119) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2000
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte studyC Haioun, E Lepage, C Gisselbrecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trialC Guglielmi, F Gomez, T Philip, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 29, 2002
Tumor necrosis factor alpha release is a major biological event associated with rituximab treatmentJ Bienvenu, R Chvetzoff, G Salles, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 12, 2012
Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-upP Colombat, N Brousse, G Salles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2005
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'AdulteP Feugier, A Van Hoof, C Sebban, et al.
Pageof 12